| Authors: |
Pecoits-Filho R; School of Medicine, Pontifical Catholic University of Parana, Curitiba, Brazil.; Arbor Research Collaborative for Health, Ann Arbor, MI, USA., Kanda E; Department of Health Data Science, Kawasaki Medical School, Kurashiki, Okayama, Japan., Kashihara N; Department of Nephrology, Kawasaki Medical School, Kurashiki, Okayama, Japan., Ofori-Asenso R; Cardiovascular, Renal, Metabolism Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Chen H; Medical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA., Pentakota S; Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Järbrink K; Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden., Garcia Sanchez JJ; Global Market Access and Pricing, AstraZeneca, Barcelona, Spain., Lam CSP; National Heart Centre Singapore and Duke National University of Singapore, Singapore., Fishbane S; Division of Nephrology, Zucker School of Medicine, Great Neck, NY, USA., Pollock C; Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia. |
